BPG is committed to discovery and dissemination of knowledge
Review
©The Author(s) 2025.
World J Gastrointest Oncol. Jul 15, 2025; 17(7): 103337
Published online Jul 15, 2025. doi: 10.4251/wjgo.v17.i7.103337
Figure 3
Figure 3 Available targeted therapeutic options for locally advanced pancreatic ductal adenocarcinoma. PDAC: Pancreatic ductal adenocarcinoma; BRCA1/2: Breast cancer susceptibility gene 1/2; palb2: Partner and localizer of breast cancer 2; MSI-H: Microsatellite instability high; dMMR: Mismatch repair deficient; NTRK: Neurotrophic receptor tyrosine kinase; nal-IRI: Nanoliposomal irinotecan; 5-FU: 5-fluorouracil; LV: Leucovorin.


Write to the Help Desk